The Emerging Role of Human Esterases

Tatsuki Fukami* and Tsuyoshi Yokoi
Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan

Summary: In this review, novel aspects of the role of esterases, which contribute to the metabolism of 10% of therapeutic drugs, are described. Esterases hydrolyze the compounds that contain ester, amide, and thioester bonds, which cause prodrug activation or detoxification. Among esterases, carboxylesterases are well known to be involved in the hydrolysis of a variety of drugs. Additionally, other esterases have recently received attention for their pharmacological and toxicological roles. Arylacetamide deacetylase (AADAC) is involved in the hydrolysis of flutamide, phenacetin, and rifamycins. AADAC is associated with adverse drug reactions because the hydrolytic metabolites of flutamide and phenacetin appear to be associated with hepatotoxicity and nephrotoxicity/hematotoxicity, respectively. Paraoxonase and butyrylcholinesterase hydrolyze picrocarpine/simvastatin and succinylcholine/bambuterol, respectively. Although the esterases that hydrolyze the acyl-glucuronides of drugs have largely been unknown, we recently found that hydrolase domain containing 10 (ABHD10) is responsible for the hydrolysis of mycophenolic acid acyl-glucuronide in human liver. Because acyl-glucuronides are associated with toxicity, ABHD10 might function as a detoxification enzyme. Thus, various esterases, which include enzymes that have not been known to hydrolyze drugs, are involved in drug metabolism with different substrate specificity. Further esterase studies should be conducted to promote our understanding in clinical pharmacotherapy and drug development.

Keywords: esterases; drug hydrolysis; activation of prodrugs; drug detoxification; drug adverse reaction

Introduction
Drug metabolism refers to the biochemical transformation of a compound into its more polar chemical form. Drug-metabolizing enzymes are responsible for the detoxification of many drugs and xenobiotics to facilitate their excretion, which is an important determinant of drug action. Drug metabolism is classified into phase I and phase II reactions. Phase I metabolism usually results in a change in molecular weight or water solubility of the substrate, and its reactions confer the sites at which phase II metabolism occurs. Phase II conjugation causes an appreciable increase in substrate molecular weight and water solubility. Of the enzymes involved in phase I reactions, cytochrome P450 enzymes play a pivotal role in drug metabolism (i.e., approximately 75% of clinically used drugs), followed by esterases, which contribute to the metabolism of 10% of the clinical, therapeutic drugs that contain ester, amide, and thioester bonds.1

Esterases are responsible for prodrug activation and drug detoxification and have been divided into 3 categories (A-, B-, and C-esterases) based on substrate specificity and sensitivity to various inhibitors (i.e., organophosphates and sulfhydryl reagents). A-esterases rapidly hydrolyze aromatic esters, which include organophosphate diisopropyl fluorophosphates (DFP). The representative A-esterase enzyme is paraoxonase (PON). B-esterases are inhibited by organophosphates, carbamate, and organosulfur compounds. In humans, most esterases, such as carboxylesterases (CESs) and cholinesterases, are B-esterases and members of the serine esterase superfamily that possess a serine residue in the conserved -Gly-X-Ser-X-Gly- motif at the active site. C-esterases neither hydrolyze organophosphate esters nor are inhibited by them. To our knowledge, the C-esterases that likely hydrolyze drugs have not been identified. Nowadays, the above classification is not generally applicable because the function of each esterase has been clarified.
Among these esterases, CES enzymes are well known for their involvement in drug metabolism. Some human esterases other than CES enzymes have also been demonstrated to hydrolyze several drugs. For example, we found that arylacetamide deacetylase (AADAC), which was previously recognized as a lipase, and α/β hydrolase containing (ABHD) 10, whose function was previously unknown, are involved in the hydrolysis of clinical drugs. Therefore, recent evidence demonstrates that various esterases are involved in drug metabolism (Table 1). A comprehensive understanding of esterases would be useful in clinical pharmacotherapy and drug development. This review describes the novel aspects of the roles of the enzymes that are responsible for drug hydrolysis.

Carboxylesterase

CES enzymes are members of the serine esterase superfamily that possesses the serine residue of the conserved -Gly-X-Ser-X-Gly- motif at the active site and are responsible for the hydrolysis of a wide variety of xenobiotic and endogenous compounds. Human CES enzymes are classified into 5 subfamilies: CES1, CES2, CES3, CES4A, and CESSA. The CES1 subfamily is composed of 2 genes, CES1 (a functional gene, previously termed CES1A1) and CES1P1 (a pseudogene, previously termed CES1A3). Previously, another functional CES1 gene (previously termed CES1A2) was reported to be located at the locus that corresponds to the CES1P1 gene, but our later study determined it to be a CES1P1 variant. The other human CES subfamilies are composed of the corresponding single gene. CES1 and CES2 are reported to be responsible for the biotransformation of a number of clinically used drugs and prodrugs. CES1 is predominantly expressed in the human liver and marginally expressed in the gastrointestinal tract. The monomeric molecular weight of CES1 is 60 kDa, and CES1 is present as a 180-kDa trimer. CES2 is expressed in the liver as well as in extrahepatic tissues, such as the gastrointestinal tract and kidney. In contrast to CES1, CES2 is a 60-kDa monomer. These CES enzymes contain a hydrophobic signal peptide at the N-terminus for trafficking through the endoplasmic reticulum and a retention sequence at the C-terminus for interacting with the Lys-Asp-Glu-Leu (KDEL) receptor. Therefore, it has been hypothesized that CES enzymes are specifically localized in the lumen side of the endoplasmic reticulum. However, CES1 and CES2 enzymes are also present in human liver cytosol at comparable levels; although, it is unclear whether cytosolic CESs initially possess no signal peptide, the signal peptide had been removed before CESs move to the endoplasmic reticulum, or CESs in endoplasmic reticulum move to the cytosol.

Although the amino acid homology of CES1 and CES2 around a serine residue in an active site is high, they exhibit significant differences in their substrate specificity. Clinical drugs such as imidapril, methylphenidate, osertamivir, and clopidogrel are specifically hydrolyzed by human CES1. Capcitabine and oxycodin are hydrolyzed by CES1 but are also hydrolyzed by CES2 to a minor extent. CPT-11 and prasugrel are preferentially hydrolyzed by CES2. A small alcohol group and large acyl group are common features of CES1 substrates, except for oxybutinin, whereas CES2 substrates have a large alcohol group and small acyl group (Table 1).
The hydrolysis of drugs that are catalyzed by CES enzymes exhibits large interindividual variability, which may be due to quantitative and qualitative differences in the CES enzymes. Our previous study reported that CES1 protein expression exhibited approximately 22-fold and 58-fold differences in microsomes and cytosol, respectively, among 12 human livers. Xu et al. reported that the CES2 protein expression exhibited 3-fold and 15-fold differences in microsomes and cytosol, respectively, among 12 human livers. Two single nucleotide polymorphisms (SNPs) of g.9486G>A and g.12754T>del were found to be associated with an increased area under the blood concentration time curve (AUC) of methylphenidate. The former SNP leads to an amino acid substitution of G143Q, and the latter substitution of R34W and V142M have been reported to cause secretion of CES1c-deleted mRNA in eukaryotic expression systems. Additionally, the difference in substrate specificity of each CES enzyme in various species is not well known, further elucidation will be required.

### Arylacetamide Deacetylase

Human arylacetamide deacetylase (AADAC), which has a molecular weight of 45 kDa, is a microsomal serine esterase that is expressed in the liver and gastrointestinal tissues. There is a single AADAC isoform in humans and other mammals. Unlike CES enzymes, AADAC is a Type II membrane protein that has an uncleaved N-terminal signal anchor sequence to retain on the lumen side of the endoplasmic reticulum. AADAC was first identified as the enzyme that catalyzes the deacetylation of the carcinogen 2-acetylaminofluorene. Although 2-acetylaminofluorene is a metabolite of aminofluorene, which is catalyzed by N-acetyltransferase (NAT), the acetyl metabolites of other known NAT substrates, such as sulfamethazine, p-aminoazobenzoic acid, procainamide, and p-aminosalicylic acid, are not hydrolyzed by AADAC. In addition to 2-acetylaminofluorene hydrolysis, AADAC has been recognized as a lipase because the active site of AADAC has strong homology with that of hormone-sensitive lipase. In fact, human AADAC was proven capable of hydrolyzing cholesterol ester when expressed in yeast.

Recently, we found that human AADAC is responsible for the hydrolysis of clinical drugs, such as flutamide, phenacetin, and rifamycins (Table 1). The clinical significance of AADAC in the hydrolysis of these drugs is described below in detail. Flutamide is a nonsteroidal antiandrogen drug that is used for the treatment of prostate cancer. It occasionally causes severe hepatotoxicity. Flutamide itself is not toxic when used at the appropriate clinical dose, but bioactivation of flutamide has been considered the cause of flutamide-induced hepatotoxicity. Flutamide is mainly metabolized to 2-hydroxyflutamide, which is associated with the therapeutic effect, by human CYP1A2 and is also hydrolyzed to 4-nitro-3-(trifluoromethyl)phenylamine (FLU-1) by AADAC and CES2. FLU-1 is an arylamine, whose N-deacetylation is generally recognized to be associated with toxicity. In fact, several studies have suggested that flutamide-induced hepatotoxicity was caused by N-deacetyl FLU-1, a metabolite of FLU-1 whose formation is catalyzed by CYP3A or CYP1A. Therefore, the hydrolysis of flutamide by AADAC and CES2 is the initial step that leads to hepatotoxicity.

Phenacetin had been widely used as an analgesic antipyretic drug, but it was withdrawn from the market because of the occurrence of renal failure and hematotoxicity in some patients. Phenacetin is mainly metabolized to
Therefore, because AADAC produces arylamines from N and are important fi are a group of structurally similar, complex macrocyclic acetylarylamine drugs, this would cause toxic effects. 

Rifamycins, such as rifampicin, rifabutin, and rifapentine, are a group of structurally similar, complex macrocyclic antibiotics that are produced by Streptomyces mediterranei and are important first-line antituberculosis drugs. The main metabolic pathway is 25-deacytolation by AADAC. Rifamycins are known to induce various drug-metabolizing enzymes, such as CYP3A4, but 25-deacetyl rifamycins exhibit no or little induction potency.

Fig. 1. Metabolic pathways of flutamide and phenacetin in humans
(A) Flutamide and (B) phenacetin are metabolized to pharmacologically active metabolites by CYP1A2. Their hydrolysis by AADAC leads to the formation of toxic metabolites.

Acetaminophen, which is a pharmacologically active metabolite, by CYP1A2 and is hydrolyzed to p-phenetidine by AADAC (Fig. 1B). p-Phenetidine is further metabolized to N-hydroxyphenetidine, which has been considered to cause renal failure and hepatotoxicity, such as methemoglobinemia and hemolytic anemia.

The common characteristics in the abovementioned AADAC substrates are that they contain a large alcohol group and small acyl group, which is similar to CES2 substrates. In fact, both AADAC and CES2 have been shown to be involved in flutamide hydrolysis in the human liver at low and high concentrations of flutamide, respectively. However, phenacetin and rifamycins are not hydrolyzed by CES2. An understanding of the substrate specificity differences between AADAC and CES2 is of interest.

When we measured flutamide hydrolysis at 500 μM, at which concentration AADAC is predominantly contributed to flutamide hydrolysis, a 50-fold interindividual variability was observed in microsomes from 24 human livers. Similarly, 22- and 205-fold interindividual variabilities in the hydrolysis activities of phenacetin (1 mM) and rifampicin (50 μM), respectively, were observed. Our recent study found a polymorphic mutation in the AADAC gene that caused diminished enzyme activity from a human liver sample with remarkably low flutamide hydrolysis activity.

Therefore, because AADAC produces arylamines from N-acetylated drugs, this would cause toxic effects.

Rifamycins, such as rifampicin, rifabutin, and rifapentine, are a group of structurally similar, complex macrocyclic antibiotics that are produced by Streptomyces mediterranei and are important first-line antituberculosis drugs. The main metabolic pathway is 25-deacyolation by AADAC. Rifamycins are known to induce various drug-metabolizing enzymes, such as CYP3A4, but 25-deacetyl rifamycins have no or little induction potency. Rifampicin has been reported to cause toxic injury to hepatocytes. However, we found that 25-desacetyl rifamycins exhibit no or less cytoxicity compared with the parent rifamycins. Therefore, human AADAC would mediate decreasing the induction rates of drug-metabolizing enzymes and hepatotoxicity by rifamycins.

The species differences in the enzyme activity, substrate specificity, and tissue distribution of AADAC were evaluated using humans and rodents (mouse and rat samples). AADAC mRNA is highly expressed in the liver as well as in the gastrointestinal tract in humans, whereas Aadac mRNA is expressed in the liver at the highest level, followed by the gastrointestinal tract (jejunum) and kidney in rodents. Recombinant mouse and rat Aadac proteins exhibited the hydrolyase activities of flutamide and phenacetin but not rifampicin. In support of this finding, rodent liver microsomes did not exhibit rifampicin hydrolyase activity. It was reported that 25-deacetyl rifampicin was detected in human plasma as the principal metabolite, whereas it was barely detected in rat and rabbit plasma. Additionally, it was reported that dog tissues were also unable to hydrolyze rifampicin. Therefore, 25-deacetyl rifampicin is likely a specific metabolite formed by human AADAC. Species differences in AADAC substrate specificity should receive attention during the preclinical drug development process.
Cholinesterase

In human cholinesterases, there are 2 principal enzymes: acetylcholinesterase (ACHE) and butyrylcholinesterase (BChE).\(^55\) ACHE is predominantly expressed in the tissues, such as brain and muscles, and erythrocytes. ACHE in tissues and erythrocytes possesses a large common catalytic domain but has a different C-terminal sequence that is produced by alternative splicing.\(^56\) ACHE exists as polymers of catalytic subunits.\(^57\) The globular forms, G1, G2, and G4, contain 1, 2, or 4 subunits, respectively. The asymmetric form, A12, contains 12 subunits. ACHE is involved in the acceleration of amyloid formation, which is associated with Alzheimer’s disease in the brain. Therefore, for the treatment of Alzheimer’s disease, several ACHE inhibitors, such as donepezil and rivastigmine, are used.\(^58\) However, knowledge concerning drugs that are hydrolyzed by ACHE is limited.

BChE is expressed in the liver, lung, brain, and heart tissues.\(^59\) BChE is predominantly present in plasma because BChE that is synthesized in the liver is secreted into the plasma. BChE has similar catalytic properties to ACHE. The G4 tetramer constitutes the majority of the plasma BChE.\(^60\) In contrast to ACHE, several drugs have been reported to be substrates of BChE. The neuromuscular blocking agents, such as succinylcholine and mivacurium, are predominantly hydrolyzed by BChE. Low plasma BChE enzyme activity, which is caused by organophosphate poisoning and BChE genetic polymorphisms, in patients is associated with prolonged apnea following clinical exposure to succinylcholine and mivacurium.\(^61\) Bambuterol, which is a \(\beta\)-adrenergic agonist that is used for the treatment of asthma, is hydrolyzed primarily by BChE to terbutaline, which is a pharmaceutically active metabolite. Bambuterol has the potency to inhibit BChE enzyme activity, resulting in the slow conversion of bambuterol to terbutaline. This can explain the long acting feature of bambuterol.

Cocaine, which is a stimulant of the central nervous system, an appetite suppressant, and a topical anesthetic, contains 2 ester bonds and is hydrolyzed to ecgonine methyl ester and benzoylecgonine.\(^62\) The ecgonine methyl ester, which is a major metabolite found in urine, is formed by hydrolysis by BCHE. However, in tissues, CES2 can also catalyze this hydrolysis reaction.\(^11\) The relative contribution of these enzymes to ecgonine methyl ester formation is unknown. A second metabolite, benzoylecgonine, which is found in urine, is produced by the cleavage of another ester bond by CES1 in human liver. Therefore, cocaine is hydrolyzed by multiple esterases to produce 2 metabolites.

CPT-11 is known to be hydrolyzed by CES and BChE enzymes.\(^65\) The \(k_m\) value of CPT-11 hydrolysis by human BChE is 42.4 \(\pm\) 10.6 \(\mu\)M, which is higher than that by human CES2 (3.4 \(\pm\) 1.4 \(\mu\)M).\(^20\) BChE is predominantly expressed in human plasma, whereas CES enzymes are expressed in human tissues, such as the liver and intestine. The contribution of human BChE to the hydrolysis of CPT-11 is unclear.

Paraoxonase

Different from esterases described above, paraoxonases (PONs) do not belong to the serine esterase family and require calcium to exert their activities and stabilities.\(^66\) The human PON family consists of three isoforms, PON1, PON2, and PON3, in which the gene loci are adjacent on the long arm of chromosome 7q21.3–22.1.\(^67\) These genes are approximately 65% homologous at the amino acid level and have similar molecular weights (43–45 kDa).\(^67\) In mammals, 3 PON isoforms are well conserved; PON orthologs share greater than 80% amino acid homology.\(^57,68\) It has been reported that PON1 and PON3 are synthesized primarily in the liver and partially secreted into the plasma, whereas PON2 is ubiquitously expressed in human tissues except plasma.\(^69\) In the liver, PON enzymes are mainly localized in the endothelial reticulum.\(^70\) PON enzymes are considered to be luminal endoplasmic reticulum proteins, because they have one disulfide bridge between Cys residues, which would favor a luminal protein orientation. In plasma, PON1 resides on the high-density lipoprotein (HDL) cholesterol-carrying particles. Apolipoprotein A-I, which is the major structural protein on HDL, appears to interact with PON1, to make PON1 highly stable and an active conformation.\(^71\)

PON1 hydrolyzes organophosphates, such as paraxon, sarin, and soman.\(^72,73\) In drug metabolism, PON1 hydrolyzes lactone- or cyclic carbonate-containing drugs, such as prulifloxacin,\(^74\) pilocarpine,\(^75\) and olmesartan medoxomil.\(^76\) Pilocarpine hydrolysis causes pharmacological inactivation, whereas prulifloxacin and olmesartan medoxomil hydrolysis causes pharmacological activation. PON enzymes exhibit a calcium-dependent activity at calcium concentrations of 0–10 \(\mu\)M and a maximum activity at a 20-\(\mu\)M calcium concentration.\(^66\) The plasma calcium concentration is normally 1 mM.\(^66\) In contrast, the calcium concentration in the endoplasmic reticulum in the liver is normally 0.1 to 1 \(\mu\)M.\(^66\) Therefore, PON could exert enzyme activity in human liver, although the activity in plasma might be higher compared with that in human liver.

PON1 has 2 common polymorphisms, L55M and Q192R. The effects of the amino acid substitution of Q192R are substrate dependent. For example, paraoxon is more efficiently hydrolyzed by PON1 192R, but soman and sarin are more efficiently hydrolyzed by 192Q.\(^77\) In drug metabolism, we previously investigated the effect of PON1 Q192R on pilocarpine hydrolysis (Fig. 2).\(^78\) Figure 2B represents the pilocarpine hydrolyase activity in 50 individual human plasma samples with different PON1 genotypes. The activities in the plasma of 192R homozygote subjects were significantly higher than those in the plasma of subjects with the 192Q polymorphism. This result was not changed by correcting the pilocarpine hydrolyase activity with phenyl acetate.
pharmacologically active

Pilocarpine

PON1

CYP2A6

3-Hydroxypilocarpine

Fig. 2. The effects of PON1 polymorphisms (Q192R) on the pilocarpine hydrolase activity in human plasma

(A) Metabolic pathways of pilocarpine in humans. Pilocarpine is metabolized to pilocarpic acid by PON1 and 3-hydroxypliocarpine by CYP2A6. These metabolites are detected in human blood and excreted into the urine at a level approximately equal to that of the parent drug pilocarpine after oral administration. Pilocarpine hydrolase activities in human plasma with different PON1 genotypes are presented with (B) raw data and (C) corrected data with the phenyl acetate hydrolase activities. Phenyl acetate hydrolase activity was used as a PON1 expression index because it was reported that the PON1 Q192R polymorphism does not affect phenyl acetate hydrolase activity. Human plasma samples from 50 Japanese subjects were used. Seven, 20, and 23 subjects were genotyped as 192Q/Q, 192Q/R, and 192R/R, respectively. Pilocarpine hydrolase activities in plasma were determined at a substrate concentration of 3 mM. *p < 0.05 compared with 192Q/Q; †p < 0.05; ǂp < 0.005 compared with 192Q/R.

Esterases Responsible for Deglucuronidation of Acyl-glucuronides

Glucuronidation that is catalyzed by UGT enzymes accounts for the metabolism of more than 35% of all drugs that are metabolized by phase II enzymes. In general, glucuronides are neither active nor reactive and are rapidly excreted from the body. However, it has been reported that acyl-glucuronides, which are formed from compounds that contain carboxylic acid, can bind covalently to proteins and other macromolecules because of their electrophilicity, which suggests that they are associated with immunogenicity and toxicity. The formed glucuronides are primarily hydrolyzed by β-glucuronidase, especially in the gut. However, because acyl-glucuronides contain an ester bond, they may be hydrolyzed by esterases that are expressed in tissues as well as β-glucuronidase. As a drug that forms acyl-glucuronide, we studied mycophenolic acid (MPA). MPA is primarily metabolized to the inactive phenolic glucuronide (MPAG) and partially to MPA acyl-glucuronide (AcMPAG) 

Although the AcMPAG deglucuronidation was detected in human liver homogenates, the deglucuronidation was not inhibited by D-saccaric acid 1,4-lactone, a β-glucuronidase inhibitor. Our recent study found by purifying the responsible enzyme from human liver cytosol (HLC) that α/β hydrolase domain containing (ABHD) 10 catalyzes the deglucuronidation of AcMPAG. The theoretical molecular weight of human ABHD10 is 34 kDa, but the purified ABHD10 shows a 28-kDa band by Western blotting. According to the National Center for Biotechnology Information database (accession number Q9NUJ1), 52 amino acids on the N-terminal end and the residual 254 amino acids of the human ABHD10 precursor are regarded as the transit peptide and mature chain, respectively. The purified ABHD10 would correspond to the mature form.
Recombinant human ABHD10 could not hydrolyze phenolic glucuronide. ABHD10 is expressed in both of HLM and HLC. The catalytic efficiency of AcMPAG formation in human liver homogenates was increased by phenylmethylsulfonyl fluoride (PMSF), which is an ABHD10 inhibitor (Fig. 3B). It has been reported that AcMPAG promotes the release of TNF-α and IL-6, which are proinflammatory cytokines, from human mononuclear leukocytes.  

Therefore, because AcMPAG appears to be associated with immunogenicity and toxicity, ABHD10 may function to protect against the adverse effects of MPA. The substrate specificity of human ABHD10 is under investigation in our laboratory. The human ABHD family consists of 19 isoforms (ABHD1–ABHD11, ABHD12A, ABHD12B, ABHD13, ABHD14A, ABHD14B, ABHD15, ABHD16A, and ABHD16B), but other than ABHD10, the involvement of ABHD enzymes in drug metabolism remains unknown.

Recently, it was reported that the deglucuronidation of valproic acid acyl-glucuronide in HLC is catalyzed by acylpeptide hydrolase (APEH). The monomeric molecular weight of APEH is 75 kDa, and APEH is present as a homotetrameric protein (300 kDa). APEH is originally recognized as the peptidase that catalyzes the hydrolysis of the N-terminus of proteins to release the N-terminal-acetylated amino acid. Information is limited for the involvement of this enzyme in drug metabolism. However, plasma valproic acid concentrations are decreased by concomitant use with carbapenem antibiotics in epileptic patients. The drug-drug interaction can be explained by the inhibition of APEH by panipenem.

Human serum albumin (HSA) has an esterase-like activity for the deglucuronidation of acyl-glucuronide of fenoprofen, etodolac, ketoprofen, and gemfibrozil. HSA is a major protein in plasma to which various compounds bind. The reversible binding of acyl-glucuronides to HSA would promote acyl-glucuronide hydrolysis. Additionally, HSA might be a target for forming a covalent adduct of acyl-glucuronide.

To date, the effect of HSA on the formation of acyl-glucuronide in the body is unknown. Various esterases and proteins catalyze acyl-glucuronide deglucuronidation. Studies of clofibric acid in rabbits and zomepirac in guinea pigs have demonstrated that esterases, rather than β-glucuronidase, are primarily involved in acyl-glucuronide deglucuronidation. Although information for rabbit and guinea pig ABHD10 was not reported, ABHD10 between human and rodents (mouse and rat) share more than 90% amino acid homology. ABHD10 has a function in drug metabolism. However, the contribution of these enzymes to the hydrolysis of acyl-glucuronide in animals remains to be clarified.

Other Enzymes Responsible for Drug Hydrolysis

This section describes the other esterases for which evidence of involvement in drug hydrolysis is accumulating. It was reported that sialic acid 9-O-acetylersterase (SIAE) enzymes that are expressed in the lysosome and cytosol were encoded by a single gene by different usage of exons at the N-terminus. Usui et al. found that SIAE is an enzyme that
catalyzes the hydrolysis of alacepril by the purification of the responsible enzyme from rat liver cytosol.\textsuperscript{107} However, they suggested that lysosomal SIAE was detected in the cytosol because frozen rat livers were used as the sample material for purification.\textsuperscript{107} It has not been examined whether cytosolic SIAE can hydrolyze alacepril. SIAE cannot hydrolyze other ACE inhibitors, which are classified as dicarboxylate-containing agents, such as imidapril, delapril, and temocapril.\textsuperscript{14} In humans, there are 2 types of SIAEs, lysosomal and cytosolic enzymes, which are similar to rat SIAEs. Human and rat SIAE showed 75% amino acid homology. To date, it is unknown whether human SIAEs can catalyze alacepril.

Olmesartan medoxomil is hydrolyzed by carboxymethyl-
enbutenolidase homolog (CMBL) in human tissues, mainly in the liver and intestine cytosol.\textsuperscript{108} As described above, PON1 also efficiently hydrolyzes olmesartan medoxomil to olmesartan in human plasma. Because it was reported that olmesartan alone was detected in plasma after the oral administration of olmesartan medoxomil,\textsuperscript{109} PON1 and CMBL in the small intestine, portal blood, and liver would be highly involved in the hydrolysis of olmesartan medoxomil. CMBL can hydrolyze faropenem medoxomil and lenampicillin, but not prulifloxacin despite their structural similarity. In contrast, PON1 hydrolyzes prulifloxacin, which demonstrates a substrate specificity difference toward CMBL.

Valacyclovir and valganciclovir are amino acid ester prodrugs of acyclovir, which is pharmacologically active. Their oral bioavailabilities are several-fold higher than that of acyclovir.\textsuperscript{110} After absorption from the gut, they are efficiently hydrolyzed to acyclovir. Kim \textit{et al.} demonstrated that one enzyme responsible for the hydrolysis of valacyclovir and valganciclovir is biphenyl hydrolase-like protein (BPHL), which is highly expressed in human intestine, liver, and kidney.\textsuperscript{111,113} The substrate specificity of BPHL resides mainly in the acyl moiety and to a lesser extent in the alcohol moiety.\textsuperscript{115} Considering the chemical structures of valacyclovir and valganciclovir, it is proposed that BPHL should be termed an \( \alpha \)-amino acid ester prodrug-activating enzyme rather than a nucleoside prodrug-activating enzyme. Considering the substrate specificity of BPHL based on the amino acid acyl group,\textsuperscript{114} new prodrugs, especially antiviral and anticancer nucleoside prodrugs, with increased absorption could be developed.

Recently, it was reported that human erythrocytes exhibit more efficient hydrolysis activity of aspirin, a classic nonsteroidal anti-inflammatory agent, rather than human plasma, and identified erythrocyte type I platelet-activating factor acetylhydrolase (PAFAH) as the responsible enzyme in human erythrocytes.\textsuperscript{115} This enzyme exists as a trimer that is composed of homo- or heterodimers of 2 catalytic subunits, either PAFAH1B3 or PAFAH1B2 and a non-catalytic PAFAH1B1 protein subunit. Aspirin ineffectiveness is observed in some individuals. The interindividual variability of PAFAH enzyme activity might cause this ineffectiveness, although aspirin hydrolysis is catalyzed by other esterases, such as CES2.\textsuperscript{14}

Aldehyde dehydrogenase (ALDH) in human liver, which is widely known to catalyze the oxidation of both aliphatic and aromatic aldehydes to their corresponding carboxylic acids, appears to participate in hydrolysis.\textsuperscript{116} Human ALDH is classified into 11 subfamilies (i.e., ALDH1–ALDH9, ALDH16, and ALDH18). Among them, several enzymes, such as ALDH1A1, ALDH2, and ALDH3A1, can catalyze the hydrolysis of \( p \)-nitrophenyl acetate.\textsuperscript{117,118} Although there are no reports that human ALDH is involved in the hydrolysis of clinical drugs that contain carboxylic esters, amides, or thioesters, ALDH2, which is localized in mitochondria, plays an important role for the hydrolysis of nitroglycerin, which contains nitroester.\textsuperscript{119} Nitroglycerin hydrolysis generates 1,2-glyceril dinitrate and nitrite (NO\textsuperscript{2–}) that is further converted to nitric oxide, which is associated with the treatment of angina pectoris. A polymorphic ALDH\textsuperscript{2} mutation is associated with a lack of nitroglycerin efficacy in Chinese patients.\textsuperscript{120}

\textbf{Conclusions and Further Prospects}

Over time, evidence has accumulated concerning the roles of esterases in drug metabolism. Prodrugs are hydrolytically activated after absorption from the gastrointestinal tract. Conversely, some drugs are hydrolytically inactivated. Additionally, drug hydrolysis is sometimes associated with toxicity. Therefore, esterases play important roles in the regulation of drug efficacy and toxicity.

The differences in the substrate specificities of esterases have not been fully elucidated. In CES enzymes, CES1 prefers substrates with a small alcohol group and large acyl group, whereas CES2 prefers substrates with a large alcohol group and small acyl group. AADAC also prefers substrates with the same characteristics as CES2. BCHE also hydrolyzes the same substrates as CES2. It will be a challenge to clarify the substrate specificity of each esterase. Furthermore, in some cases, the hydrolysis of a drug is catalyzed by more than 2 esterases in various tissues and blood. Predicting the contribution of each esterase to the hydrolysis of drugs in the body is also important.

There are several clinical drugs for which the esterase(s) that are involved in their hydrolysis are unknown. Additionally, there are uncharacterized esterases involved in the hydrolysis of clinical drugs. Unidentified esterase(s) involved in drug metabolism may exist in humans. Further studies of esterases that catalyze the hydrolysis of clinical drugs will facilitate our understanding of the pharmacological and toxicological importance of esterases.

\textbf{Acknowledgments:} We thank Dr. Miki Nakajima (Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan) for comments on this manuscript.
References


Human Esterases Responsible for Drug Metabolism


